Navigation Links
ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Date:12/16/2009

.

During the development and progression of RA, the recruitment of immune cells, both innate and adaptive, into affected joints plays a key role in the inflammatory process and the ensuing joint destruction. There is strong evidence implicating CCR1 in the pathology of RA. ChemoCentryx's approach to specifically target the CCR1 receptor with CCX354 represents a new mechanism of action in the potential treatment of RA. CCX354 falls within the scope of the strategic alliance with GlaxoSmithKline through its Center of Excellence for External Drug Discovery (CEEDD).

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase 2/3 multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, successfully concluded a Phase 1 clinical program. Additional clinical programs include CCX140, which targets the CCR2 receptor, expected to enter Phase 2 clinical development in the first quarter of 2010 for the treatment of type 2 diabetes mellitus, and CCX354, a CCR1 antagonist in a Phase 2 clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
2. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
6. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
7. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
8. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
9. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
10. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
11. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and TORONTO , Aug. ... (OTCQB: GNBT) today announced the issuance of a white ... proprietary buccal insulin spray product.  The white paper was ... the Company,s stockholders by Dr. James H. Anderson, ... white paper may be viewed online on the Generex ...
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... , August 27, 2015 ... Persistence Market Research titled "Global Market Study on ... Growth by 2021", the urinary catheters market is expected to ... of 2015. It is anticipated to expand at ... reach US$1,755.0 Mn by 2021. View ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... MILFORD, Mass., Nov. 14, 2011 PLC Systems Inc. ... technologies, today reported financial results for the three and ... only include the company,s RenalGuard® operations, since PLC completed ... Novadaq Corp. during the first quarter of 2011. Results ...
... (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy ... corporate overview at the Lazard Capital Markets 8th Annual Healthcare ... in New York. A live audio webcast ... webcast will also be archived for 90 days. ...
Cached Medicine Technology:PLC Systems Reports Third Quarter 2011 Results 2PLC Systems Reports Third Quarter 2011 Results 3PLC Systems Reports Third Quarter 2011 Results 4PLC Systems Reports Third Quarter 2011 Results 5PLC Systems Reports Third Quarter 2011 Results 6Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2
(Date:8/27/2015)... ... 2015 , ... According to an article published August 13 by ... many conversations between hernia experts surrounding the search for the ideal hernia mesh. With ... experts have different ideas about which is the best mesh for their patients. What ...
(Date:8/27/2015)... ... 27, 2015 , ... In an article published July 30th by ... of New Orleans, highlighting a security firm that is tasked with providing supplemental protection. ... entrepreneur who worked with the city to provide private security when it is needed ...
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, at the Adams County ... of the “Music With A Mission” benefit concert. For the past two years, “Music ... the underfunded school districts of Mendon and neighboring town, Quincy, IL. Organized in part ...
(Date:8/27/2015)... PLAINSBORO, N.J. and WILMINGTON, Del. (PRWEB) , ... August 27, 2015 ... ... at Texas Children’s Hospital, will be the guest speaker at CURE® magazine’s 3rd ... meeting of hematologists. , Dr. Arnold will be among hundreds of attendees honoring eight ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4
... offers tips on digestive disorders , , SATURDAY, March 28 (HealthDay ... a one-time bellyache, but it also could be a sign ... Boland, chief of gastroenterology at Baylor University Medical Center in ... digestive disorders: , Symptoms : Alert your ...
... safe and superior to bare metal stents in preventing ... in a nationwide registry of cardiovascular disease, according to ... findings were presented today at the i2Summit at the ... also appear online in the Journal of the ...
... more than $19 billion dollars of funding provided for ... stimulus package offers a unique opportunity to deliver on ... Children,s Hospital Boston in a Perspective article published in ... Journal of Medicine (NEJM). The co-authors argue that ...
... DRx Corporation (Nasdaq: VETS ) a provider of ... announced that the Company will release its financial results for ... to the opening of the market on Wednesday, April 1, ... call on Thursday, April 2, beginning at 2:00 p.m. Eastern ...
... to pay restitution of $2.3 billion and forfeit $1.7 ... Enterprises (NCFE) executives were sentenced today for their roles ... health of NCFE, Acting Assistant Attorney General Rita M. ... Southern District of Ohio announced. NCFE, formerly based in ...
... flu shot, will have Tamiflu available for purchase as well. , ... Van Nuys, CA ... influenza virus that is easily caught upon contact with the virus. The flu ... fatal. The best prevention of the flu is to get the annual ...
Cached Medicine News:Health News:What You Need to Know When Your Stomach Aches 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Billions spent on health IT stimulus could lead to major boom... or bust 2Health News:Pet DRx to Hold Its Fourth Quarter and Year-End 2008 Financial Results Conference Call 2Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 2Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 3Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 4Health News:Nationwide Medical/Surgical Announces Availability of Tamiflu for the 2009-2010 Influenza Season 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: